Legend Biotech's Stock Soars Amid Takeover Bid Rumors

Legend Biotech, a CAR-T specialist known for its collaboration with Johnson & Johnson on the BCMA CAR-T therapy Carvykti, has reportedly received a takeover bid. In response, Legend has enlisted Centerview Partners as a financial adviser to evaluate its options. This news spurred a significant market reaction, with Legend Biotech’s stock price climbing approximately 12% on the Nasdaq and GenScript, Legend's largest shareholder, experiencing a 25% surge in Hong Kong. Despite these developments, GenScript stated it had no insider information to disclose that would justify the stock movement, while Legend declined to comment on the market rumors.

The potential acquisition of Legend Biotech is notable given its successful partnership with Johnson & Johnson, which values the peak sales potential of Carvykti at over $5 billion. This collaboration, initiated in 2017, positioned Legend as a prominent player in biopharma, with shared responsibilities and profits in the development and commercialization of Carvykti. The existing relationship between Legend and Johnson & Johnson fuels speculation that Johnson & Johnson could be interested in acquiring Legend, although the New Jersey pharma has not yet commented on the matter. Historically, major pharmaceutical companies have pursued similar acquisitions, as seen with Sanofi's purchase of Provention Bio and Pfizer's acquisition of Biohaven Pharma.

Additionally, the timing of this report coincides with a broader biosecurity crackdown on Chinese biopharma service providers under the proposed BIOSECURE Act. This scrutiny includes GenScript and its related entities, though there is no current indication that GenScript or Legend will be targeted. A strategic move by Johnson & Johnson to acquire Legend could mitigate potential risks associated with these geopolitical tensions. Alternatively, Novartis, which recently entered a $100 million agreement with Legend for DLL3-directed CAR-T candidates and has a manufacturing deal for Carvykti, might also be a viable suitor. However, Novartis's acquisition focus and the competitive landscape, including AstraZeneca's recent acquisition of Gracell Biotechnologies, suggest a complex scenario for Legend's future.

Click here to read the original news story.